Just to alleviate some confusion out there, Dr. Kausik Ray will deliver the AHA Late Breaking Presentation on BETonMACE. Dr. Ray is one of the most well known and well respected cardiologists in the world. He specializes in investigating the cardiovascular risks presented by diabetes, elevated lipids (i.e. LDL-C, apoB, etc) and inflammation. He is the lead clinical investigator of BETonMACE and head of the BETonMACE clinical steering committee. He is also involved in many exciting clinical trials including but not limited to Esperion's bempedoic acid CLEAR program and The Medicine Company's inclisiran ORION program. When Dr. Ray talks, people listen. If you haven't had the joy of hearing him speak before, you're missing out. Some of this past presentations can be found here.

https://www.imperial.ac.uk/people/k.ray

https://www.eas-society.org/page/ray_bio

https://www.kausikray.com/

So what to expect at the AHA Late Breaking presentation? Click the link below for the schedule for this session.

LBS.01 - Late Breaking Science I: Outside the Box: New Approaches to CVD Risk Reduction

Four main presentations between 10:45 AM and 12:10 PM. Each of the four has a 3 minute "Setting the Stage" segment to provide some background and introduction (thanks to Barsax over on Stockhouse for pointing this out). This is followed by the 8 minute long clinical trial presentation. This is followed by a 10 minute discussion period focused on that particular clinical trial. Following the four presentations, there is an additional 10 minute discussion period that is likely open to questions on any of the four trials. 

BETonMACE is the last of the four, which is great! The 10 minute BETonMACE discussion period is immediately followed the the 10 minute additional discussion period. So BETonMACE will be fresh in everyone's mind when the open discussion period begins.

Here are the BETonMACE devoted portions of the session: intro, main presentation, discussion.

 Setting the Stage: Epigenetics and CVD Risk; The Next Target?

Svati H Shah, Hillsborough, NC

- Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial

Kausik K Ray, Imperial Coll London, London, United Kingdom

- Discussant

Svati H Shah, Hillsborough, NC